Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients

M. Zambetti, R. Demicheli, D. De Candis, G. Antonelli, A. Giacobone, M. Terenziani, A. Laffranchi, F. Garbagnati, S. Biasi, G. Bonadonna

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The aim of the present study was to evaluate the clinical activity and side effects of a combination chemotherapy consisting of a five-day continuous infusion of fluorouracil and i.v. vinorelbine in metastatic previously treated breast cancer patients. The patient population was represented by 28 women with evaluable disease, previously subjected to chemotherapy, including anthracycline-containing regimens in 89% of patients. Treatment consisted of five-day infusion of 700 mg/m2/day of fluorouracil and vinorelbine, 20 mg/m2 iv bolus on day 1 and 6. In the absence of Grade > 3 leukopenia and stomatitis, cycles were repeated every three weeks, for a total of six cycles. Four complete and thirteen partial responses were documented, accounting for a response rate of 61% (95% CI: 40.5-78.5); the clinical efficacy was high even in patients unresponsive to prior anthracycline treatment. The median response duration calculated from the first drug injection was 8 months (range 4-11). Treatment was well tolerated, with 4% Grade 4 stomatitis and 20% Grade 3 leukopenia as the main toxic reactions. This drug combination is active in metastatic previously treated breast cancer patients, is devoid of severe side effects, and warrants further testing.

Original languageEnglish
Pages (from-to)255-260
Number of pages6
JournalBreast Cancer Research and Treatment
Volume44
Issue number3
DOIs
Publication statusPublished - 1997

Fingerprint

Fluorouracil
Breast Neoplasms
Stomatitis
Anthracyclines
Leukopenia
Poisons
Drug Combinations
Combination Drug Therapy
Therapeutics
vinorelbine
Drug Therapy
Injections
Pharmaceutical Preparations
Population

Keywords

  • Chemotherapy
  • Fluorouracil (infusion)
  • Metastatic breast cancer
  • Salvage treatment
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. / Zambetti, M.; Demicheli, R.; De Candis, D.; Antonelli, G.; Giacobone, A.; Terenziani, M.; Laffranchi, A.; Garbagnati, F.; Biasi, S.; Bonadonna, G.

In: Breast Cancer Research and Treatment, Vol. 44, No. 3, 1997, p. 255-260.

Research output: Contribution to journalArticle

Zambetti, M, Demicheli, R, De Candis, D, Antonelli, G, Giacobone, A, Terenziani, M, Laffranchi, A, Garbagnati, F, Biasi, S & Bonadonna, G 1997, 'Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients', Breast Cancer Research and Treatment, vol. 44, no. 3, pp. 255-260. https://doi.org/10.1023/A:1005769604001
Zambetti, M. ; Demicheli, R. ; De Candis, D. ; Antonelli, G. ; Giacobone, A. ; Terenziani, M. ; Laffranchi, A. ; Garbagnati, F. ; Biasi, S. ; Bonadonna, G. / Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. In: Breast Cancer Research and Treatment. 1997 ; Vol. 44, No. 3. pp. 255-260.
@article{a6e5bdaebee74722ba2cc53e54ec6de9,
title = "Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients",
abstract = "The aim of the present study was to evaluate the clinical activity and side effects of a combination chemotherapy consisting of a five-day continuous infusion of fluorouracil and i.v. vinorelbine in metastatic previously treated breast cancer patients. The patient population was represented by 28 women with evaluable disease, previously subjected to chemotherapy, including anthracycline-containing regimens in 89{\%} of patients. Treatment consisted of five-day infusion of 700 mg/m2/day of fluorouracil and vinorelbine, 20 mg/m2 iv bolus on day 1 and 6. In the absence of Grade > 3 leukopenia and stomatitis, cycles were repeated every three weeks, for a total of six cycles. Four complete and thirteen partial responses were documented, accounting for a response rate of 61{\%} (95{\%} CI: 40.5-78.5); the clinical efficacy was high even in patients unresponsive to prior anthracycline treatment. The median response duration calculated from the first drug injection was 8 months (range 4-11). Treatment was well tolerated, with 4{\%} Grade 4 stomatitis and 20{\%} Grade 3 leukopenia as the main toxic reactions. This drug combination is active in metastatic previously treated breast cancer patients, is devoid of severe side effects, and warrants further testing.",
keywords = "Chemotherapy, Fluorouracil (infusion), Metastatic breast cancer, Salvage treatment, Vinorelbine",
author = "M. Zambetti and R. Demicheli and {De Candis}, D. and G. Antonelli and A. Giacobone and M. Terenziani and A. Laffranchi and F. Garbagnati and S. Biasi and G. Bonadonna",
year = "1997",
doi = "10.1023/A:1005769604001",
language = "English",
volume = "44",
pages = "255--260",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients

AU - Zambetti, M.

AU - Demicheli, R.

AU - De Candis, D.

AU - Antonelli, G.

AU - Giacobone, A.

AU - Terenziani, M.

AU - Laffranchi, A.

AU - Garbagnati, F.

AU - Biasi, S.

AU - Bonadonna, G.

PY - 1997

Y1 - 1997

N2 - The aim of the present study was to evaluate the clinical activity and side effects of a combination chemotherapy consisting of a five-day continuous infusion of fluorouracil and i.v. vinorelbine in metastatic previously treated breast cancer patients. The patient population was represented by 28 women with evaluable disease, previously subjected to chemotherapy, including anthracycline-containing regimens in 89% of patients. Treatment consisted of five-day infusion of 700 mg/m2/day of fluorouracil and vinorelbine, 20 mg/m2 iv bolus on day 1 and 6. In the absence of Grade > 3 leukopenia and stomatitis, cycles were repeated every three weeks, for a total of six cycles. Four complete and thirteen partial responses were documented, accounting for a response rate of 61% (95% CI: 40.5-78.5); the clinical efficacy was high even in patients unresponsive to prior anthracycline treatment. The median response duration calculated from the first drug injection was 8 months (range 4-11). Treatment was well tolerated, with 4% Grade 4 stomatitis and 20% Grade 3 leukopenia as the main toxic reactions. This drug combination is active in metastatic previously treated breast cancer patients, is devoid of severe side effects, and warrants further testing.

AB - The aim of the present study was to evaluate the clinical activity and side effects of a combination chemotherapy consisting of a five-day continuous infusion of fluorouracil and i.v. vinorelbine in metastatic previously treated breast cancer patients. The patient population was represented by 28 women with evaluable disease, previously subjected to chemotherapy, including anthracycline-containing regimens in 89% of patients. Treatment consisted of five-day infusion of 700 mg/m2/day of fluorouracil and vinorelbine, 20 mg/m2 iv bolus on day 1 and 6. In the absence of Grade > 3 leukopenia and stomatitis, cycles were repeated every three weeks, for a total of six cycles. Four complete and thirteen partial responses were documented, accounting for a response rate of 61% (95% CI: 40.5-78.5); the clinical efficacy was high even in patients unresponsive to prior anthracycline treatment. The median response duration calculated from the first drug injection was 8 months (range 4-11). Treatment was well tolerated, with 4% Grade 4 stomatitis and 20% Grade 3 leukopenia as the main toxic reactions. This drug combination is active in metastatic previously treated breast cancer patients, is devoid of severe side effects, and warrants further testing.

KW - Chemotherapy

KW - Fluorouracil (infusion)

KW - Metastatic breast cancer

KW - Salvage treatment

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=8544247167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544247167&partnerID=8YFLogxK

U2 - 10.1023/A:1005769604001

DO - 10.1023/A:1005769604001

M3 - Article

C2 - 9266105

AN - SCOPUS:8544247167

VL - 44

SP - 255

EP - 260

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -